The global Neuromyelitis Optica Drug market is projected to grow from US$ 49 million in 2024 to US$ 58 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.0% during the forecast period.

Neuromyelitis Optica Drug Market

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Market Analysis and Insights: Global Neuromyelitis Optica Drug Market

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

Report Covers:

This report presents an overview of global market for Neuromyelitis Optica Drug market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Neuromyelitis Optica Drug, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Neuromyelitis Optica Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuromyelitis Optica Drug revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Neuromyelitis Optica Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Neuromyelitis Optica Drug revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Neuromyelitis Optica Drug Market Report

Report Metric	Details
Report Name	Neuromyelitis Optica Drug Market
Accounted market size in 2024	US$ 49 million
Forecasted market size in 2030	US$ 58 million
CAGR	3.0
Base Year	2024
Forecasted years	2024 - 2030
Segment by Type	Glucocorticoids Immunotherapies Others
Segment by Application	Acute Attack Remission Prophylactic Treatment
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Neuromyelitis Optica Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuromyelitis Optica Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Drug revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Neuromyelitis Optica Drug Market growing?

Ans: The Neuromyelitis Optica Drug Market witnessing a CAGR of 3.0 during the forecast period 2024-2030.

What is the Neuromyelitis Optica Drug Market size in 2030?

Ans: The Neuromyelitis Optica Drug Market size in 2030 will be US$ 58 million.

What is the Neuromyelitis Optica Drug Market share by region?

Ans: Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

What is the market share of major companies in Neuromyelitis Optica Drug Market?

Ans: Top 3 companies occupied about 35% market share.

Who are the main players in the Neuromyelitis Optica Drug Market report?

Ans: The main players in the Neuromyelitis Optica Drug Market are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP

What are the Application segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Applications covered in the Neuromyelitis Optica Drug Market report are Acute Attack, Remission Prophylactic Treatment

What are the Type segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Types covered in the Neuromyelitis Optica Drug Market report are Glucocorticoids, Immunotherapies, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Glucocorticoids

1.2.3 Immunotherapies

1.2.4 Others

1.3 Market by Application

1.3.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Acute Attack

1.3.3 Remission Prophylactic Treatment

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neuromyelitis Optica Drug Market Perspective (2019-2030)

2.2 Global Neuromyelitis Optica Drug Growth Trends by Region

2.2.1 Neuromyelitis Optica Drug Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Neuromyelitis Optica Drug Historic Market Size by Region (2019-2024)

2.2.3 Neuromyelitis Optica Drug Forecasted Market Size by Region (2025-2030)

2.3 Neuromyelitis Optica Drug Market Dynamics

2.3.1 Neuromyelitis Optica Drug Industry Trends

2.3.2 Neuromyelitis Optica Drug Market Drivers

2.3.3 Neuromyelitis Optica Drug Market Challenges

2.3.4 Neuromyelitis Optica Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Neuromyelitis Optica Drug by Players

3.1.1 Global Neuromyelitis Optica Drug Revenue by Players (2019-2024)

3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2019-2024)

3.2 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Neuromyelitis Optica Drug, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Neuromyelitis Optica Drug Market Concentration Ratio

3.4.1 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Drug Revenue in 2023

3.5 Global Key Players of Neuromyelitis Optica Drug Head office and Area Served

3.6 Global Key Players of Neuromyelitis Optica Drug, Product and Application

3.7 Global Key Players of Neuromyelitis Optica Drug, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Neuromyelitis Optica Drug Breakdown Data by Type

4.1 Global Neuromyelitis Optica Drug Historic Market Size by Type (2019-2024)

4.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2025-2030)

5 Neuromyelitis Optica Drug Breakdown Data by Application

5.1 Global Neuromyelitis Optica Drug Historic Market Size by Application (2019-2024)

5.2 Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Neuromyelitis Optica Drug Market Size (2019-2030)

6.2 North America Neuromyelitis Optica Drug Market Size by Type

6.2.1 North America Neuromyelitis Optica Drug Market Size by Type (2019-2024)

6.2.2 North America Neuromyelitis Optica Drug Market Size by Type (2025-2030)

6.2.3 North America Neuromyelitis Optica Drug Market Share by Type (2019-2030)

6.3 North America Neuromyelitis Optica Drug Market Size by Application

6.3.1 North America Neuromyelitis Optica Drug Market Size by Application (2019-2024)

6.3.2 North America Neuromyelitis Optica Drug Market Size by Application (2025-2030)

6.3.3 North America Neuromyelitis Optica Drug Market Share by Application (2019-2030)

6.4 North America Neuromyelitis Optica Drug Market Size by Country

6.4.1 North America Neuromyelitis Optica Drug Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Neuromyelitis Optica Drug Market Size by Country (2019-2024)

6.4.3 North America Neuromyelitis Optica Drug Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Neuromyelitis Optica Drug Market Size (2019-2030)

7.2 Europe Neuromyelitis Optica Drug Market Size by Type

7.2.1 Europe Neuromyelitis Optica Drug Market Size by Type (2019-2024)

7.2.2 Europe Neuromyelitis Optica Drug Market Size by Type (2025-2030)

7.2.3 Europe Neuromyelitis Optica Drug Market Share by Type (2019-2030)

7.3 Europe Neuromyelitis Optica Drug Market Size by Application

7.3.1 Europe Neuromyelitis Optica Drug Market Size by Application (2019-2024)

7.3.2 Europe Neuromyelitis Optica Drug Market Size by Application (2025-2030)

7.3.3 Europe Neuromyelitis Optica Drug Market Share by Application (2019-2030)

7.4 Europe Neuromyelitis Optica Drug Market Size by Country

7.4.1 Europe Neuromyelitis Optica Drug Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Neuromyelitis Optica Drug Market Size by Country (2019-2024)

7.4.3 Europe Neuromyelitis Optica Drug Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Neuromyelitis Optica Drug Market Size (2019-2030)

8.2 China Neuromyelitis Optica Drug Market Size by Type

8.2.1 China Neuromyelitis Optica Drug Market Size by Type (2019-2024)

8.2.2 China Neuromyelitis Optica Drug Market Size by Type (2025-2030)

8.2.3 China Neuromyelitis Optica Drug Market Share by Type (2019-2030)

8.3 China Neuromyelitis Optica Drug Market Size by Application

8.3.1 China Neuromyelitis Optica Drug Market Size by Application (2019-2024)

8.3.2 China Neuromyelitis Optica Drug Market Size by Application (2025-2030)

8.3.3 China Neuromyelitis Optica Drug Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Neuromyelitis Optica Drug Market Size (2019-2030)

9.2 Asia Neuromyelitis Optica Drug Market Size by Type

9.2.1 Asia Neuromyelitis Optica Drug Market Size by Type (2019-2024)

9.2.2 Asia Neuromyelitis Optica Drug Market Size by Type (2025-2030)

9.2.3 Asia Neuromyelitis Optica Drug Market Share by Type (2019-2030)

9.3 Asia Neuromyelitis Optica Drug Market Size by Application

9.3.1 Asia Neuromyelitis Optica Drug Market Size by Application (2019-2024)

9.3.2 Asia Neuromyelitis Optica Drug Market Size by Application (2025-2030)

9.3.3 Asia Neuromyelitis Optica Drug Market Share by Application (2019-2030)

9.4 Asia Neuromyelitis Optica Drug Market Size by Region

9.4.1 Asia Neuromyelitis Optica Drug Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Neuromyelitis Optica Drug Market Size by Region (2019-2024)

9.4.3 Asia Neuromyelitis Optica Drug Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type

10.2.1 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application

10.3.1 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country

10.4.1 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Neuromyelitis Optica Drug Introduction

11.1.4 Pfizer Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.1.5 Pfizer Recent Developments

11.2 Fresenius

11.2.1 Fresenius Company Details

11.2.2 Fresenius Business Overview

11.2.3 Fresenius Neuromyelitis Optica Drug Introduction

11.2.4 Fresenius Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.2.5 Fresenius Recent Developments

11.3 Teva

11.3.1 Teva Company Details

11.3.2 Teva Business Overview

11.3.3 Teva Neuromyelitis Optica Drug Introduction

11.3.4 Teva Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.3.5 Teva Recent Developments

11.4 Sandoz

11.4.1 Sandoz Company Details

11.4.2 Sandoz Business Overview

11.4.3 Sandoz Neuromyelitis Optica Drug Introduction

11.4.4 Sandoz Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.4.5 Sandoz Recent Developments

11.5 Intas

11.5.1 Intas Company Details

11.5.2 Intas Business Overview

11.5.3 Intas Neuromyelitis Optica Drug Introduction

11.5.4 Intas Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.5.5 Intas Recent Developments

11.6 Gyjtrs

11.6.1 Gyjtrs Company Details

11.6.2 Gyjtrs Business Overview

11.6.3 Gyjtrs Neuromyelitis Optica Drug Introduction

11.6.4 Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.6.5 Gyjtrs Recent Developments

11.7 NANG KUANG

11.7.1 NANG KUANG Company Details

11.7.2 NANG KUANG Business Overview

11.7.3 NANG KUANG Neuromyelitis Optica Drug Introduction

11.7.4 NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.7.5 NANG KUANG Recent Developments

11.8 Tianjin Kingyork

11.8.1 Tianjin Kingyork Company Details

11.8.2 Tianjin Kingyork Business Overview

11.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Introduction

11.8.4 Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.8.5 Tianjin Kingyork Recent Developments

11.9 Baxter

11.9.1 Baxter Company Details

11.9.2 Baxter Business Overview

11.9.3 Baxter Neuromyelitis Optica Drug Introduction

11.9.4 Baxter Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.9.5 Baxter Recent Developments

11.10 CSL

11.10.1 CSL Company Details

11.10.2 CSL Business Overview

11.10.3 CSL Neuromyelitis Optica Drug Introduction

11.10.4 CSL Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.10.5 CSL Recent Developments

11.11 Grifols

11.11.1 Grifols Company Details

11.11.2 Grifols Business Overview

11.11.3 Grifols Neuromyelitis Optica Drug Introduction

11.11.4 Grifols Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.11.5 Grifols Recent Developments

11.12 Octapharma

11.12.1 Octapharma Company Details

11.12.2 Octapharma Business Overview

11.12.3 Octapharma Neuromyelitis Optica Drug Introduction

11.12.4 Octapharma Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.12.5 Octapharma Recent Developments

11.13 CBOP

11.13.1 CBOP Company Details

11.13.2 CBOP Business Overview

11.13.3 CBOP Neuromyelitis Optica Drug Introduction

11.13.4 CBOP Revenue in Neuromyelitis Optica Drug Business (2019-2024)

11.13.5 CBOP Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Glucocorticoids

Table 3. Key Players of Immunotherapies

Table 4. Key Players of Others

Table 5. Global Neuromyelitis Optica Drug Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 6. Global Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Neuromyelitis Optica Drug Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Neuromyelitis Optica Drug Market Share by Region (2019-2024)

Table 9. Global Neuromyelitis Optica Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Neuromyelitis Optica Drug Market Share by Region (2025-2030)

Table 11. Neuromyelitis Optica Drug Market Trends

Table 12. Neuromyelitis Optica Drug Market Drivers

Table 13. Neuromyelitis Optica Drug Market Challenges

Table 14. Neuromyelitis Optica Drug Market Restraints

Table 15. Global Neuromyelitis Optica Drug Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Neuromyelitis Optica Drug Revenue Share by Players (2019-2024)

Table 17. Global Top Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2023)

Table 18. Global Neuromyelitis Optica Drug Industry Ranking 2022 VS 2023 VS 2024

Table 19. Global 5 Largest Players Market Share by Neuromyelitis Optica Drug Revenue (CR5 and HHI) & (2019-2024)

Table 20. Global Key Players of Neuromyelitis Optica Drug, Headquarters and Area Served

Table 21. Global Key Players of Neuromyelitis Optica Drug, Product and Application

Table 22. Global Key Players of Neuromyelitis Optica Drug, Product and Application

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2024)

Table 26. Global Neuromyelitis Optica Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2025-2030)

Table 28. Global Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Neuromyelitis Optica Drug Revenue Share by Application (2019-2024)

Table 30. Global Neuromyelitis Optica Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Neuromyelitis Optica Drug Revenue Share by Application (2025-2030)

Table 32. North America Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)

Table 33. North America Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)

Table 34. North America Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)

Table 35. North America Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)

Table 36. North America Neuromyelitis Optica Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. North America Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)

Table 38. North America Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)

Table 39. Europe Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)

Table 40. Europe Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)

Table 41. Europe Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)

Table 42. Europe Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)

Table 43. Europe Neuromyelitis Optica Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Europe Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)

Table 45. Europe Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)

Table 46. China Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)

Table 47. China Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)

Table 48. China Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)

Table 49. China Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)

Table 50. Asia Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)

Table 51. Asia Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)

Table 52. Asia Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)

Table 53. Asia Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)

Table 54. Asia Neuromyelitis Optica Drug Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 55. Asia Neuromyelitis Optica Drug Market Size by Region (2019-2024) & (US$ Million)

Table 56. Asia Neuromyelitis Optica Drug Market Size by Region (2025-2030) & (US$ Million)

Table 57. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type (2019-2024) & (US$ Million)

Table 58. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Type (2025-2030) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application (2019-2024) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Application (2025-2030) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 62. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country (2019-2024) & (US$ Million)

Table 63. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size by Country (2025-2030) & (US$ Million)

Table 64. Pfizer Company Details

Table 65. Pfizer Business Overview

Table 66. Pfizer Neuromyelitis Optica Drug Product

Table 67. Pfizer Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 68. Pfizer Recent Developments

Table 69. Fresenius Company Details

Table 70. Fresenius Business Overview

Table 71. Fresenius Neuromyelitis Optica Drug Product

Table 72. Fresenius Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 73. Fresenius Recent Developments

Table 74. Teva Company Details

Table 75. Teva Business Overview

Table 76. Teva Neuromyelitis Optica Drug Product

Table 77. Teva Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 78. Teva Recent Developments

Table 79. Sandoz Company Details

Table 80. Sandoz Business Overview

Table 81. Sandoz Neuromyelitis Optica Drug Product

Table 82. Sandoz Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 83. Sandoz Recent Developments

Table 84. Intas Company Details

Table 85. Intas Business Overview

Table 86. Intas Neuromyelitis Optica Drug Product

Table 87. Intas Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 88. Intas Recent Developments

Table 89. Gyjtrs Company Details

Table 90. Gyjtrs Business Overview

Table 91. Gyjtrs Neuromyelitis Optica Drug Product

Table 92. Gyjtrs Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 93. Gyjtrs Recent Developments

Table 94. NANG KUANG Company Details

Table 95. NANG KUANG Business Overview

Table 96. NANG KUANG Neuromyelitis Optica Drug Product

Table 97. NANG KUANG Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 98. NANG KUANG Recent Developments

Table 99. Tianjin Kingyork Company Details

Table 100. Tianjin Kingyork Business Overview

Table 101. Tianjin Kingyork Neuromyelitis Optica Drug Product

Table 102. Tianjin Kingyork Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 103. Tianjin Kingyork Recent Developments

Table 104. Baxter Company Details

Table 105. Baxter Business Overview

Table 106. Baxter Neuromyelitis Optica Drug Product

Table 107. Baxter Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 108. Baxter Recent Developments

Table 109. CSL Company Details

Table 110. CSL Business Overview

Table 111. CSL Neuromyelitis Optica Drug Product

Table 112. CSL Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 113. CSL Recent Developments

Table 114. Grifols Company Details

Table 115. Grifols Business Overview

Table 116. Grifols Neuromyelitis Optica Drug Product

Table 117. Grifols Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 118. Grifols Recent Developments

Table 119. Octapharma Company Details

Table 120. Octapharma Business Overview

Table 121. Octapharma Neuromyelitis Optica Drug Product

Table 122. Octapharma Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 123. Octapharma Recent Developments

Table 124. CBOP Company Details

Table 125. CBOP Business Overview

Table 126. CBOP Neuromyelitis Optica Drug Product

Table 127. CBOP Revenue in Neuromyelitis Optica Drug Business (2019-2024) & (US$ Million)

Table 128. CBOP Recent Developments

Table 129. Research Programs/Design for This Report

Table 130. Key Data Information from Secondary Sources

Table 131. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Neuromyelitis Optica Drug Market Share by Type: 2023 VS 2030

Figure 3. Glucocorticoids Features

Figure 4. Immunotherapies Features

Figure 5. Others Features

Figure 6. Global Neuromyelitis Optica Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 7. Global Neuromyelitis Optica Drug Market Share by Application: 2023 VS 2030

Figure 8. Acute Attack Case Studies

Figure 9. Remission Prophylactic Treatment Case Studies

Figure 10. Neuromyelitis Optica Drug Report Years Considered

Figure 11. Global Neuromyelitis Optica Drug Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Neuromyelitis Optica Drug Market Share by Region: 2023 VS 2030

Figure 14. Global Neuromyelitis Optica Drug Market Share by Players in 2023

Figure 15. Global Top Neuromyelitis Optica Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Drug Revenue in 2023

Figure 17. North America Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Neuromyelitis Optica Drug Market Share by Type (2019-2030)

Figure 19. North America Neuromyelitis Optica Drug Market Share by Application (2019-2030)

Figure 20. North America Neuromyelitis Optica Drug Market Share by Country (2019-2030)

Figure 21. United States Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Neuromyelitis Optica Drug Market Size YoY (2019-2030) & (US$ Million)

Figure 24. Europe Neuromyelitis Optica Drug Market Share by Type (2019-2030)

Figure 25. Europe Neuromyelitis Optica Drug Market Share by Application (2019-2030)

Figure 26. Europe Neuromyelitis Optica Drug Market Share by Country (2019-2030)

Figure 27. Germany Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. China Neuromyelitis Optica Drug Market Size YoY (2019-2030) & (US$ Million)

Figure 34. China Neuromyelitis Optica Drug Market Share by Type (2019-2030)

Figure 35. China Neuromyelitis Optica Drug Market Share by Application (2019-2030)

Figure 36. Asia Neuromyelitis Optica Drug Market Size YoY (2019-2030) & (US$ Million)

Figure 37. Asia Neuromyelitis Optica Drug Market Share by Type (2019-2030)

Figure 38. Asia Neuromyelitis Optica Drug Market Share by Application (2019-2030)

Figure 39. Asia Neuromyelitis Optica Drug Market Share by Region (2019-2030)

Figure 40. Japan Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. South Korea Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. China Taiwan Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. India Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Australia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Size YoY (2019-2030) & (US$ Million)

Figure 47. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Type (2019-2030)

Figure 48. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Application (2019-2030)

Figure 49. Middle East, Africa, and Latin America Neuromyelitis Optica Drug Market Share by Country (2019-2030)

Figure 50. Brazil Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Mexico Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 52. Turkey Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Israel Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. GCC Countries Neuromyelitis Optica Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Pfizer Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 57. Fresenius Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 58. Teva Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 59. Sandoz Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 60. Intas Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 61. Gyjtrs Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 62. NANG KUANG Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 63. Tianjin Kingyork Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 64. Baxter Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 65. CSL Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 66. Grifols Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 67. Octapharma Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 68. CBOP Revenue Growth Rate in Neuromyelitis Optica Drug Business (2019-2024)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions